Kelun-Biotech to present Phase 3 sacituzumab tirumotecan data at ESMO 2026
Kelun-Biotech will present Phase 3 results for sacituzumab tirumotecan in metastatic NSCLC and advanced endometrial cancer at ESMO 2026 in Madrid on Oct. 25-26.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.